Daniel J Deangelo

List of Publications by Year
in descending order

232 papers	17,832 citations	24978 57 h-index	14156 128 g-index
235 all docs	235 docs citations	235 times ranked	17534 citing authors

#	Article	IF	Citations
1	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Advances, 2022, 6, 818-827.	2.5	5
2	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood, 2022, 139, 1135-1146.	0.6	39
3	Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Advances, 2022, 6, 72-81.	2.5	7
4	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. Clinical Cancer Research, 2022, 28, 870-881.	3.2	32
5	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 2022, 15, 1.	6.9	33
6	Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. Blood Advances, 2022, 6, 2835-2846.	2.5	8
7	Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leukemia and Lymphoma, 2022, 63, 1934-1941.	0.6	13
8	Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. British Journal of Haematology, 2022, 198, 421-430.	1.2	1
9	Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Experimental Hematology, 2022, 107, 14-19.	0.2	10
10	Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e836-e843.	0.2	1
11	Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Advances, 2022, 6, 5750-5762.	2.5	20
12	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. Journal of Clinical Oncology, 2022, 40, 3709-3718.	0.8	9
13	Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia, 2022, 36, 2108-2120.	3.3	22
14	Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical and Translational Science, 2021, 14, 184-193.	1.5	3
15	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 2021, 137, 2463-2480.	0.6	35
16	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. Leukemia, 2021, 35, 1166-1175.	3.3	5
17	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosomeâ€“positive relapsed/refractory acute lymphoblastic leukemia. Cancer, 2021, 127, 905-913.	2.0	30
18	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research, 2021, 27, 2742-2754.	3.2	16

#	Article	IF	Citations
19	Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell, 2021, 28, 514-523.e9.	5.2	130
20	Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Science Translational Medicine, 2021, 13, .	5.8	29
21	Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. Haematologica, 2021, 106, 1787-1793.	1.7	5
22	Pretreatment clinical and genetic factors predict early postâ€treatment mortality in fit <scp>AML</scp> patients following induction. American Journal of Hematology, 2021, 96, E259-E262.	2.0	1
23	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood, 2021, 138, 11-22.	0.6	90
24	The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood, 2021, 138, 898-911.	0.6	27
25	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, The, 2021, 398, 491-502.	6.3	315
26	Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Advances, 2021, 5, 4352-4360.	2.5	14
27	Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Advances, 2021, 5, 5536-5545.	2.5	24
28	Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study. Blood, 2021, 138, 4406-4406.	0.6	1
29	Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138, 1284-1284.	0.6	0
30	Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax. Blood, 2021, 138, 4126-4126.	0.6	0
31	Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study. Blood, 2021, 138, 2565-2565.	0.6	2
32	Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic. Blood, 2021, 138, 2291-2291.	0.6	2
33	Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. Blood, 2021, 138, 318-318.	0.6	16
34	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 4440-4440.	0.6	2
35	A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138, 4429-4429.	0.6	1
36	Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 372-372.	0.6	13

#	Article	IF	Citations
37	A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults. Blood, 2021, 138, 2305-2305.	0.6	12
38	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine, 2021, 27, 2183-2191.	15.2	78
39	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nature Medicine, 2021, 27, 2192-2199.	15.2	79
40	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Modern Pathology, 2020, 33, 1135-1145.	2.9	12
41	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e122-e133.	2.2	19
42	Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to reâ€induction chemotherapy. American Journal of Hematology, 2020, 95, 245-250.	2.0	13
43	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research, 2020, 88, 106283.	0.4	32
44	Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer Journal, 2020, 10, 81.	2.8	34
45	Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S44-S47.	0.2	3
46	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. British Journal of Haematology, 2020, 191, e77-e81.	1.2	3
47	Recent Advances in Managing Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 330-342.	1.8	40
48	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leukemia and Lymphoma, 2020, 61, 2012-2015.	0.6	10
49	A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Advances, 2020, 4, 1683-1689.	2.5	43
50	The prevention and management of asparaginaseâ€related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 278-284.	1.9	26
51	Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis. Blood, 2020, 136, 41-42.	0.6	6
52	Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. Blood, 2020, 136, 37-38.	0.6	10
53	Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 40-41.	0.6	10
54	Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1385-1415.	2.3	147

#	Article	IF	Citations
55	Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. Journal of Clinical Pathology, 2019, 72, 93-96.	1.0	4
56	Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist, 2019, 24, 247-254.	1.9	55
57	Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood, 2019, 134, 867-879.	0.6	55
58	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research, 2019, 85, 106197.	0.4	16
59	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer, 2019, 125, 3845-3852.	2.0	10
60	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77
61	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 1720-1729.	2.0	53
62	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and longâ€term survival followâ€up from the randomized, phase 3 INOâ€VATE study. Cancer, 2019, 125, 2474-2487.	2.0	210
63	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia, 2019, 33, 2393-2402.	3.3	44
64	Tâ€cell acute lymphoblastic leukemia: Current approach and future directions. Advances in Cell and Gene Therapy, 2019, 2, e70.	0.6	4
65	Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. Leukemia Research Reports, 2019, 12, 100189.	0.2	2
66	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 2019, 381, 2315-2326.	13.9	257
67	Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic Leukemia. ACG Case Reports Journal, 2019, 6, e00207.	0.2	0
68	Single 6-mg dose of rasburicase: The experience in a large academic medical center. Journal of Oncology Pharmacy Practice, 2019, 25, 1349-1356.	0.5	6
69	Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology, 2019, 94, 408-416.	2.0	11
70	Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTcâ€concentration modelling. British Journal of Clinical Pharmacology, 2019, 85, 590-600.	1.1	12
71	Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia (AML). Blood, 2019, 134, 3908-3908.	0.6	7
72	Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. Blood, 2019, 134, 2950-2950.	0.6	2

#	Article	IF	Citations
73	How to treat chronic myeloid leukemia (CML) in older adults. Journal of Geriatric Oncology, 2018, 9, 291-295.	0.5	6
74	Exploiting an Asp-Glu â€œswitchâ€•in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine, 2018, 10, .	5.8	69
75	Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. Journal of Clinical Pathology, 2018, 71, 653-658.	1.0	9
76	A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected. Oncology and Therapy, 2018, 6, 9-20.	1.0	19
77	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	5.8	299
78	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 725.	3.4	111
79	Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INOâ€VATE. Cancer, 2018, 124, 1722-1732.	2.0	43
80	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. Journal of Thrombosis and Thrombolysis, 2018, 45, 306-314.	1.0	31
81	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood, 2018, 131, 2816-2825.	0.6	64
82	Ponatinib efficacy and safety in Philadelphia chromosomeâ€“positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404.	0.6	392
83	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood, 2018, 131, 387-396.	0.6	131
84	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. American Journal of Hematology, 2018, 93, 254-261.	2.0	12
85	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. Journal of Hematology and Oncology, 2018, 11, 143.	6.9	52
86	New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 3504-3519.	0.8	67
87	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. British Journal of Cancer, 2018, 118, 1425-1433.	2.9	72
88	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood, 2018, 132, 1125-1133.	0.6	60
89	Treatment of young adults with Philadelphiaâ€negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyperâ€CVAD vs. pediatricâ€inspired regimens. American Journal of Hematology, 2018, 93, 1254-1266.	2.0	29
90	Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. Journal of Neuropathology and Experimental Neurology, 2018, 77, 877-882.	0.9	95

#	Article	IF	Citations
91	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or highâ€risk MDS: Phase 2 study results. American Journal of Hematology, 2018, 93, 1301-1310.	2.0	98
92	Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). Blood, 2018, 132, 351-351.	0.6	15
93	Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML). Blood, 2018, 132, 3895-3895.	0.6	0
94	Tailored Approaches to Induction Therapy for Acute Promyelocytic Leukemia. Journal of Clinical Oncology, 2017, 35, 583-586.	0.8	4
95	Selfâ€reported sleep disturbance and survival in myelodysplastic syndromes. British Journal of Haematology, 2017, 177, 562-566.	1.2	16
96	Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. Histopathology, 2017, 71, 112-124.	1.6	10
97	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature Medicine, 2017, 23, 301-313.	15.2	79
98	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood, 2017, 130, 722-731.	0.6	1,173
99	Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. Therapeutic Advances in Hematology, 2017, 8, 3-12.	1.1	5
100	Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Review of Hematology, 2017, 10, 1033-1045.	1.0	14
101	Current challenges and opportunities in treating adult patients with Philadelphiaâ€negative acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 705-723.	1.2	18
102	A precision therapy against cancers driven by KIT/PDGFRA mutations. Science Translational Medicine, 2017, 9, .	5.8	157
103	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1091-1102.	2.3	67
104	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematology,the, 2017, 4, e387-e398.	2.2	158
105	Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice. Current Hematologic Malignancy Reports, 2017, 12, 370-379.	1.2	15
106	Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Advances, 2017, 1, 1167-1180.	2.5	103
107	A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 2017, 1, 331-340.	2.5	57
108	Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Advances, 2017, 1, 1786-1789.	2.5	13

#	Article	IF	Citations
109	Neutrophil FcÎ³RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. Journal of Clinical Investigation, 2017, 127, 3810-3826.	3.9	48
110	GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study. Blood, 2017, 130, 894-894.	0.6	9
111	QoL of pediatric-inspired compared to hyper-CVAD regimens for newly diagnosed AYA patients with Ph-ALL: A modeling analysis.. Journal of Clinical Oncology, 2017, 35, e22002-e22002.	0.8	1
112	Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e302-e312.	1.8	8
113	Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer, 2016, 122, 2379-2388.	2.0	23
114	Pediatricâ€inspired therapy compared to allografting for <scp>P</scp>hiladelphia chromosomeâ€negative adult ALL in first complete remission. American Journal of Hematology, 2016, 91, 322-329.	2.0	72
115	Allogeneic transplantation is not superior to chemotherapy in most patients over 40Âyears of age with Philadelphiaâ€negative acute lymphoblastic leukemia in first remission. American Journal of Hematology, 2016, 91, 793-799.	2.0	14
116	NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1505-1512.	2.3	57
117	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematology,the, 2016, 3, e276-e283.	2.2	19
118	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	7.7	227
119	Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <scp>FLT</scp>3â€<scp>ITD</scp> acute myeloid leukaemia in first complete remission. British Journal of Haematology, 2016, 175, 496-504.	1.2	162
120	Targeting MTHFD2 in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 1285-1306.	4.2	118
121	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2016, 375, 740-753.	13.9	1,047
122	Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. Journal of Clinical Investigation, 2016, 126, 3827-3836.	3.9	40
123	Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM). Blood, 2016, 128, 477-477.	0.6	12
124	Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget, 2016, 7, 20152-20165.	0.8	22
125	A Distributed International Patient Data Registry for Hairy Cell Leukemia. Blood, 2016, 128, 5986-5986.	0.6	0
126	RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Reports, 2015, 13, 2345-2352.	2.9	28

#	Article	IF	Citations
127	The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2015, 2015, 400-405.	0.9	16
128	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood, 2015, 125, 1367-1376.	0.6	747
129	Acute Lymphoblastic Leukemia, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1240-1279.	2.3	116
130	Health care utilization and endâ€ofâ€life care for older patients with acute myeloid leukemia. Cancer, 2015, 121, 2840-2848.	2.0	113
131	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Modern Pathology, 2015, 28, 965-976.	2.9	31
132	Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay. Journal of Physical Education and Sports Management, 2015, 1, a000307.	0.5	13
133	Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. Journal of Geriatric Oncology, 2015, 6, 288-298.	0.5	29
134	Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leukemia Research, 2015, 39, 204-210.	0.4	13
135	Epidemiologic Investigation of a Cluster of Neuroinvasive Bacillus cereus Infections in 5 Patients With Acute Myelogenous Leukemia. Open Forum Infectious Diseases, 2015, 2, ofv096.	0.4	13
136	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 29-41.	7.7	95
137	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the Î³-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Journal of Physical Education and Sports Management, 2015, 1, a000539.	0.5	47
138	A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma. Blood, 2015, 126, 1328-1328.	0.6	43
139	ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. Blood, 2015, 126, 138-138.	0.6	22
140	DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. Blood, 2015, 126, 2549-2549.	0.6	5
141	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. Blood, 2015, 126, 2861-2861.	0.6	7
142	Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. Blood, 2015, 126, 323-323.	0.6	57
143	A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood, 2015, 126, 324-324.	0.6	26
144	Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. Blood, 2015, 126, 4025-4025.	0.6	7

#	Article	IF	Citations
145	SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. Blood, 2015, 126, 454-454.	0.6	29
146	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. Blood, 2015, 126, 80-80.	0.6	38
147	A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. Blood, 2015, 126, 2553-2553.	0.6	0
148	Targeting MTHFD2 in Acute Myeloid Leukemia. Blood, 2015, 126, 443-443.	0.6	2
149	Identification of CKMT1B As a New Target in EVI1-Positive AML. Blood, 2015, 126, 3674-3674.	0.6	0
150	Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. Blood, 2015, 126, 2126-2126.	0.6	0
151	Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. Blood, 2015, 126, 5142-5142.	0.6	0
152	A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2015, 126, 2550-2550.	0.6	0
153	Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML. Blood, 2015, 126, 870-870.	0.6	0
154	Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML. Blood, 2015, 126, 326-326.	0.6	0
155	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. Blood, 2015, 126, 1304-1304.	0.6	0
156	Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3310-3310.	0.6	0
157	Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 245-251.	0.2	6
158	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. Cancer Discovery, 2014, 4, 1074-1087.	7.7	201
159	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 226-242.	7.7	126
160	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leukemia Research, 2014, 38, 430-434.	0.4	23
161	The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling. Molecular and Cellular Biology, 2014, 34, 2517-2532.	1.1	48
162	AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood, 2014, 123, 905-913.	0.6	205

#	Article	IF	Citations
163	A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage. Blood, 2014, 124, 2255-2255.	0.6	18
164	The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial. Blood, 2014, 124, 968-968.	0.6	34
165	Switching drugs midstream for patients with chronic myeloid leukemia. Clinical Advances in Hematology and Oncology, 2014, 12, 466-8.	0.3	0
166	Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. Cancer, 2013, 119, 90-98.	2.0	104
167	Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia Research, 2013, 37, 1016-1020.	0.4	26
168	Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leukemia Research, 2013, 37, 747-751.	0.4	16
169	Phase <scp>II</scp> trial of panobinostat, an oral panâ€deacetylase inhibitor in patients with primary myelofibrosis, postâ€“essential thrombocythaemia, and postâ€“polycythaemia vera myelofibrosis. British Journal of Haematology, 2013, 162, 326-335.	1.2	61
170	Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1053-7.	1.4	6
171	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood, 2013, 121, 2393-2401.	0.6	122
172	A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. Blood, 2013, 122, 1437-1437.	0.6	12
173	MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. Blood, 2013, 122, 1443-1443.	0.6	4
174	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). Blood, 2013, 122, 1496-1496.	0.6	4
175	BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia. Blood, 2013, 122, 238-238.	0.6	2
176	Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 3906-3906.	0.6	9
177	Flow Cytometric Evaluation Of Minimal Residual Disease In Adult Acute Lymphoblastic Leukemia Using a Simplified, Single-Tube Approach. Blood, 2013, 122, 1378-1378.	0.6	0
178	HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. Blood, 2013, 122, 2528-2528.	0.6	0
179	Targeting Oncogenic Interleukein-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2535-2535.	0.6	0
180	The Safety and Adherence To Prophylactic Anticoagulation During Induction Chemotherapy In Adults With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 3867-3867.	0.6	0

#	Article	IF	Citations
181	Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors. Blood, 2013, 122, 3749-3749.	0.6	3
182	Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML. Cell, 2012, 151, 344-355.	13.5	294
183	The intersection of genetic and chemical genomic screens identifies GSK-3Î± as a target in human acute myeloid leukemia. Journal of Clinical Investigation, 2012, 122, 935-947.	3.9	96
184	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. Blood, 2012, 120, 230-230.	0.6	14
185	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. Blood, 2012, 120, 3747-3747.	0.6	6
186	Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. Blood, 2012, 120, 3749-3749.	0.6	2
187	Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. Blood, 2012, 120, 3763-3763.	0.6	5
188	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq0 0 0 rgBT /Overlock 1	0.6	
189	Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.. Blood, 2012, 120, 2792-2792.	0.6	0
190	Geriatric Assessment Variables Add Prognostic Value to the International Prognostic Scoring System. Blood, 2012, 120, 4933-4933.	0.6	0
191	Prospective Cohort Study of Geriatric Assessment in Older Patients with Acute Myeloid Leukemia. Blood, 2012, 120, 4285-4285.	0.6	15
192	Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy. Science, 2011, 334, 1129-1133.	6.0	502
193	Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leukemia and Lymphoma, 2011, 52, 2237-2253.	0.6	198
194	Preface. Hematology/Oncology Clinics of North America, 2011, 25, ix-x.	0.9	0
195	The frequency and management of asparaginaseâ€related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Danaâ€Farber Cancer Institute consortium protocols. British Journal of Haematology, 2011, 152, 452-459.	1.2	216
196	Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients. Blood, 2011, 118, 239-239.	0.6	0
197	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. Blood, 2011, 118, 1442-1442.	0.6	0
198	Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3. Journal of Clinical Oncology, 2010, 28, 4339-4345.	0.8	442

#	Article	IF	Citations
199	Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leukemia and Lymphoma, 2010, 51, 363-375.	0.6	13
200	KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial. Blood, 2010, 116, 316-316.	0.6	33
201	The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study. Blood, 2010, 116, 658-658.	0.6	7
202	Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3Î± (GSK-3Î±) as a Modulator of Differentiation In Acute Myeloid Leukemia. Blood, 2010, 116, 1000-1000.	0.6	0
203	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. JAMA - Journal of the American Medical Association, 2009, 301, 2349.	3.8	758
204	Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Hematology/Oncology Clinics of North America, 2009, 23, 1121-1135.	0.9	35
205	Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 984-1023.	2.3	151
206	Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood, 2009, 114, 4027-4033.	0.6	52
207	Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.. Blood, 2009, 114, 2209-2209.	0.6	22
208	Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.. Blood, 2009, 114, 2898-2898.	0.6	7
209	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. Blood, 2009, 114, 3073-3073.	0.6	1
210	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 587-587.	0.6	2
211	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. Blood, 2008, 112, 1011-1011.	0.6	1
212	Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.. Blood, 2008, 112, 958-958.	0.6	32
213	Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. Journal of Clinical Oncology, 2007, 25, 813-819.	0.8	171
214	Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood, 2007, 109, 5136-5142.	0.6	287
215	Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project. Leukemia Research, 2007, 31, 599-604.	0.4	164
216	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4496-4496.	0.6	2

#	Article	IF	Citations
217	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 587-587.	0.6	47
218	JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations.. Blood, 2007, 110, 1634-1634.	0.6	0
219	Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood, 2006, 108, 3477-3483.	0.6	194
220	Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).. Blood, 2006, 108, 158-158.	0.6	12
221	A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 1858-1858.	0.6	4
222	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. Blood, 2006, 108, 259-259.	0.6	1
223	A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without CloretazineÂ® in Patients with First Relapse of Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 1970-1970.	0.6	0
224	Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005, 105, 54-60.	0.6	632
225	The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Hematology American Society of Hematology Education Program, 2005, 2005, 123-130.	0.9	50
226	Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.. Blood, 2005, 106, 2788-2788.	0.6	0
227	Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation. Clinical Cancer Research, 2004, 10, 5065-5071.	3.2	72
228	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	0.6	0
229	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	0.6	2
230	A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. New England Journal of Medicine, 2003, 348, 1201-1214.	13.9	1,655
231	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 2003, 102, 1578-1582.	0.6	299
232	Differentiation and reversal of malignant changes in colon cancer through PPARÎ³. Nature Medicine, 1998, 4, 1046-1052.	15.2	933